The long-awaited results of a phase II basket study (NCT02601950) of the EZH2 inhibitor tazemetostat in 129 patients with solid tumors harboring SWI/SNF alterations have been published, including a dedicated cohort of 14 patients with renal medullary carcinoma (RMC). While some activity was observed in malignant rhabdoid tumors (9% response rate), INI1-negative tumors (9%), and poorly differentiated chordoma (6%), no objective responses were seen in the RMC cohort, and the futility threshold was reached. These disappointing efficacy results align with a previously reported case documenting glial transdifferentiation of an RMC brain metastasis following tazemetostat therapy, raising concern that EZH2 inhibition may provoke unwanted cell plasticity in SMARCB1-deficient RMC rather than suppress it. Tazemetostat has since been withdrawn from all trials and markets due to safety concerns, closing this chapter of EZH2-directed monotherapy for RMC and reinforcing that future epigenetic strategies for this disease will require careful combination approaches and rigorous monitoring for treatment-induced plasticity.